Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.leukres.2007.11.025
DC FieldValue
dc.titleIn vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor
dc.contributor.authorZhou, J.
dc.contributor.authorKhng, J.
dc.contributor.authorJasinghe, V.J.
dc.contributor.authorBi, C.
dc.contributor.authorPoon, L.F.
dc.contributor.authorXie, Z.
dc.contributor.authorChen, C.-S.
dc.contributor.authorNeo, C.H.S.
dc.contributor.authorPan, M.
dc.contributor.authorYu, H.
dc.contributor.authorYeoh, A.E.-J.
dc.contributor.authorLu, Y.
dc.contributor.authorGlaser, K.B.
dc.contributor.authorAlbert, D.H.
dc.contributor.authorDavidsen, S.K.
dc.date.accessioned2011-09-27T05:43:23Z
dc.date.available2011-09-27T05:43:23Z
dc.date.issued2008
dc.identifier.citationZhou, J., Khng, J., Jasinghe, V.J., Bi, C., Poon, L.F., Xie, Z., Chen, C.-S., Neo, C.H.S., Pan, M., Yu, H., Yeoh, A.E.-J., Lu, Y., Glaser, K.B., Albert, D.H., Davidsen, S.K. (2008). In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor. Leukemia Research 32 (7) : 1091-1100. ScholarBank@NUS Repository. https://doi.org/10.1016/j.leukres.2007.11.025
dc.identifier.issn01452126
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/26977
dc.description.abstractNeoangiogenesis plays an important role in leukemogenesis. We investigated the in vivo anti-leukemic effect of ABT-869 against AML with wild-type FLT3 using RFP transfected HL60 cells with in vivo imaging technology on both the subcutaneous and systemic leukemia xenograft models. ABT-869 showed a five-fold inhibition of tumor growth in comparison with vehicle control. IHC analysis revealed that ABT-869 decreased p-VEGFR1, Ki-67 labeling index, VEGF and remarkably increased apoptotic cells in the xenograft models. ABT-869 also reduced the leukemia burden and prolonged survival. Our study supports the rationale for clinically testing an anti-angiogenesis agent in AML with wild-type FLT3. © 2007 Elsevier Ltd. All rights reserved.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.leukres.2007.11.025
dc.sourceScopus
dc.subjectAcute myeloid leukemia
dc.subjectIn vivo
dc.subjectTyrosine kinase inhibitor
dc.subjectWhole-body imaging technology
dc.subjectWild-type FLT3 receptor
dc.typeArticle
dc.contributor.departmentPHYSIOLOGY
dc.contributor.departmentPAEDIATRICS
dc.contributor.departmentMEDICINE
dc.description.doi10.1016/j.leukres.2007.11.025
dc.description.sourcetitleLeukemia Research
dc.description.volume32
dc.description.issue7
dc.description.page1091-1100
dc.identifier.isiut000255856000013
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

24
checked on Apr 1, 2020

WEB OF SCIENCETM
Citations

21
checked on Mar 24, 2020

Page view(s)

214
checked on Apr 1, 2020

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.